Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis

Marius M. Hoeper; Christine Pausch; Karen M. Olsson; Dörte Huscher; David Pittrow; Ekkehard Grünig; Gerd Staehler; Carmine Dario Vizza; Henning Gall; Oliver Distler; Christian Opitz; J. Simon R. Gibbs; Marion Delcroix; Hossein Ardeschir Ghofrani; Ralf Ewert; Harald Kaemmerer; Hans‐Joachim Kabitz; Dirk Skowasch; Jürgen Behr; Katrin Milger; Michael Halank; Heinrike Wilkens; Hans‐Jürgen Seyfarth; Matthias Held; Daniel Dumitrescu; Iraklis Tsangaris; Anton Vonk Noordegraaf; Silvia Ulrich; Hans Klose; Martin Claussen; Stephan Eisenmann; Kai‐Helge Schmidt; Stephan Rosenkranz; Tobias Lange

doi:10.1016/j.healun.2022.03.011

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

While sole improvements in 6MWD and NT-proBNP had minor prognostic relevance, improvements in multicomponent endpoints and risk stratification tools based on FC, 6MWD, and NT-proBNP were associated with improved survival. These tools should be further explored as outcome measures in PAH trials.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hoeper et al. (2022) studied this question.

synapsesocial.com/papers/69d576e0e1904fea15e91343 https://doi.org/10.1016/j.healun.2022.03.011

View Full Paper

Ask AI

Bookmark

Share

Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis

Ask about this paper

Abstract

Discussion

Cite This Study

Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading